Free Trial

United Therapeutics (UTHR) Competitors

United Therapeutics logo
$309.72 +8.33 (+2.76%)
Closing price 08/13/2025 04:00 PM Eastern
Extended Trading
$310.25 +0.53 (+0.17%)
As of 04:05 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UTHR vs. BIIB, INCY, NBIX, BMRN, EXEL, EXAS, HALO, MDGL, IONS, and RGEN

Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Madrigal Pharmaceuticals (MDGL), Ionis Pharmaceuticals (IONS), and Repligen (RGEN). These companies are all part of the "biotechnology" industry.

United Therapeutics vs. Its Competitors

Biogen (NASDAQ:BIIB) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

In the previous week, Biogen had 17 more articles in the media than United Therapeutics. MarketBeat recorded 38 mentions for Biogen and 21 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.23 beat Biogen's score of 0.88 indicating that United Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
21 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
United Therapeutics
15 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Biogen presently has a consensus target price of $185.63, suggesting a potential upside of 37.29%. United Therapeutics has a consensus target price of $382.00, suggesting a potential upside of 23.34%. Given Biogen's higher possible upside, equities research analysts clearly believe Biogen is more favorable than United Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
0 Sell rating(s)
21 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.34
United Therapeutics
0 Sell rating(s)
4 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.69

87.9% of Biogen shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 0.2% of Biogen shares are held by insiders. Comparatively, 10.3% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Biogen has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.68B2.05$1.63B$10.4612.93
United Therapeutics$2.88B4.86$1.20B$25.6212.09

Biogen has a beta of 0.13, meaning that its stock price is 87% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.

United Therapeutics has a net margin of 40.36% compared to Biogen's net margin of 15.31%. United Therapeutics' return on equity of 18.73% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen15.31% 13.85% 8.32%
United Therapeutics 40.36%18.73%16.49%

Summary

United Therapeutics beats Biogen on 10 of the 16 factors compared between the two stocks.

Get United Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UTHR vs. The Competition

MetricUnited TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$13.59B$2.43B$5.54B$9.82B
Dividend YieldN/A1.78%4.62%4.12%
P/E Ratio12.0922.3830.1526.03
Price / Sales4.86729.02461.08104.76
Price / Cash10.61183.0237.7558.93
Price / Book1.954.708.476.06
Net Income$1.20B$31.61M$3.26B$265.11M
7 Day Performance3.44%3.66%4.18%3.38%
1 Month Performance4.04%3.10%4.63%2.28%
1 Year Performance-4.37%7.73%34.93%29.67%

United Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UTHR
United Therapeutics
4.8669 of 5 stars
$309.72
+2.8%
$382.00
+23.3%
-4.3%$13.59B$2.88B12.091,305Positive News
Analyst Forecast
BIIB
Biogen
4.9569 of 5 stars
$132.20
+0.2%
$185.63
+40.4%
-33.7%$19.38B$9.68B12.647,605Trending News
Analyst Revision
INCY
Incyte
4.7569 of 5 stars
$78.04
+3.2%
$79.73
+2.2%
+38.4%$15.24B$4.58B17.742,617
NBIX
Neurocrine Biosciences
4.9087 of 5 stars
$128.04
-0.7%
$160.90
+25.7%
-12.7%$12.70B$2.36B37.881,800Positive News
Insider Trade
BMRN
BioMarin Pharmaceutical
4.9971 of 5 stars
$60.31
+3.7%
$93.74
+55.4%
-35.9%$11.57B$2.95B22.423,040News Coverage
Positive News
High Trading Volume
EXEL
Exelixis
4.9459 of 5 stars
$36.81
-1.2%
$44.44
+20.7%
+44.2%$9.91B$2.23B17.701,147Positive News
Analyst Forecast
EXAS
Exact Sciences
4.7312 of 5 stars
$46.83
-1.9%
$70.50
+50.5%
-23.6%$8.83B$2.76B-8.507,000Trending News
Analyst Forecast
Analyst Revision
HALO
Halozyme Therapeutics
4.8525 of 5 stars
$59.99
+1.6%
$62.70
+4.5%
+16.3%$7.39B$1.02B15.95390Positive News
Insider Trade
MDGL
Madrigal Pharmaceuticals
3.8857 of 5 stars
$312.11
+3.3%
$420.63
+34.8%
+53.3%$6.93B$180.13M-17.2990Trending News
Analyst Forecast
Insider Trade
IONS
Ionis Pharmaceuticals
4.561 of 5 stars
$43.45
+1.0%
$59.38
+36.7%
-8.1%$6.93B$705M-23.611,069Analyst Forecast
RGEN
Repligen
4.9379 of 5 stars
$116.50
-2.0%
$169.45
+45.5%
-22.7%$6.54B$634.44M-465.981,778Positive News
Insider Trade

Related Companies and Tools


This page (NASDAQ:UTHR) was last updated on 8/14/2025 by MarketBeat.com Staff
From Our Partners